Aims: To explore previously unreported rates and trends in opioid-related mortality in Israel, 2005–2014. Methods: Data was obtained from the national database on causes of death. Drug poisoning deaths were divided into opioid-related deaths and deaths related to other drugs according to International Classification of Diseases (ICD)-10 code of underlying cause, and included drug poisoning of accidental, intentional or undetermined intent. Age-adjusted rates were calculated per 100,000 population. Rate ratios were calculated and a logistic model constructed to compare the risk of opioid-related deaths in both halves of the decade (2006–2009 and 2009–2013) and between various demographic groups. Results: While age-adjusted rates of deaths related to other drugs remained relatively stable, rates of opioid-related deaths significantly decreased during this period across all groups. During the study period, the number of opioid-related deaths in Israel declined from 1.3 to 0.3 per 100,000. Opioid-related deaths were more common among men, young adults and immigrants from the Former Soviet Union. Conclusions: Rates of opioid-related deaths in Israel were low compared to those reported in the United States and United Kingdom. In addition, the decline in opioid-related deaths in Israel is contrary to trends observed in the United States and United Kingdom. Factors that may contribute to these differences are discussed.

1.
Manchikanti L, Helm S 2nd, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV: Opioid epidemic in the United States. Pain Physician 2012; 15:ES9–ES38.
2.
Manchikanti L, Fellows B, Ailinani H, Pampati V: Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13: 401–435.
3.
Kuehn BM: Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297: 249–251.
4.
Fischer B, Gooch J, Goldman B, Kurdyak P, Rehm J: Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later. Can J Public Health 2014; 105:e146–e149.
5.
International Narcotics Control Board (INCB) Narcotic Drugs Technical Report: Estimated World Requirements for 2014 – Statistics for 2012 (No. T.14.XI.2). New York, NY, 2014.
6.
Fischer B, Keates A, Buhringer G, Reimer J, Rehm J: Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2014; 109: 177–181.
7.
National Health Service: Addiction to Medicine: An Investigation into the Configuration and Commissioning of Treatment Services to Support those who Develop Problems with Prescription-Only or Over-the-Counter Medicine, National Health Service (NHS). National Treatment Agency for Substance Misuse, 2011
8.
DCAMC: Opioid Consumption Chart, Drug Control and Access to Medicines Consortium (DCAMC). 2012.
9.
Shvartzman P, Freud T, Singer Y, Brill S, Sherf M, Battat E, Vardy D: Opioid use in an Israeli health maintenance organization: 2000–2006. Pain Med 2009; 10: 702–707.
10.
International Narcotics Control Board: Global Opioid Consumption, 2015, Pain & Policy Studies Group (PPSG), 2017.
11.
Harel-Fisch Y, Zadok Y, Hizi S: Israel Country Overview, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2016.
12.
Schiff M, Levit S, Moreno RC: Retention and illicit drug use among methadone patients in Israel: a gender comparison. Addict Behav 2007; 32: 2108–2119.
13.
Volkow ND, McLellan AT: Opioid abuse in chronic pain – misconceptions and mitigation strategies. N Engl J Med 2016; 374: 1253–1263.
14.
Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309: 657–659.
15.
Hakkinen M, Launiainen T, Vuori E, Ojanpera I: Comparison of fatal poisonings by prescription opioids. Forensic Sci Int 2012; 222: 327–331.
16.
Hakkinen M, Launiainen T, Vuori E, Ojanpera I: Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2012; 68: 301–309.
17.
Office for National Statistics: Deaths Related to Drug Poisoning in England and Wales: 2012 Registration. Newport, 2014.
18.
Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL: Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 241–248.
19.
Center for Behavioral Health Statistics and Quality: 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, Substance Abuse and Mental Health Services Administration, 2015.
20.
Rudd RA, Aleshire N, Zibbell JE, Gladden RM: Increases in drug and opioid overdose deaths – United States, 2000–2014, MMWR Morb Mortal Wkly, 2016, pp 1378–1382.
21.
Office for National Statistics: Deaths Related to Drug Poisoning in England and Wales: 2014 Registration. Newport, 2015.
22.
Cicero TJ, Ellis MS, Harney J: Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 2015; 373: 1789–1790.
23.
Compton WM, Jones CM, Baldwin GT: Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016; 374: 154–163.
24.
Leshem E: Integration of Immigrants from the Former Soviet Union 1990–2005: A Multi-Disciplinary Infrastructure Research. Jerusalem, Joint Distribution Committee, 2009.
25.
Carta MG, Bernal M, Hardoy MC, Haro-Abad JM: Migration and mental health in Europe (the state of the mental health in Europe working group: appendix 1). Clin Pract Epidemiol Ment Health 2005; 1: 13.
26.
Schiff M, Rahav G, Teichman M: Israel 2000: immigration and gender differences in alcohol consumption. Am J Addict 2005; 14: 234–247.
27.
Turner RJ, Lloyd DA, Taylor J: Stress burden, drug dependence and the nativity paradox among U.S. Hispanics. Drug Alcohol Depend 2006; 83: 79–89.
28.
Conroy MS: Abuse of drugs other than alcohol and tobacco in the Soviet Union. Soviet Studies 1990; 42: 447–480.
29.
Ott JJ, Paltiel AM, Becher H: Noncommunicable disease mortality and life expectancy in immigrants to Israel from the former Soviet Union: country of origin compared with host country. Bull World Health Organ 2009; 87: 20–29.
30.
Office for National Statistics: Deaths Related to Drug Poisoning in England and Wales: 2015 Registrations. Newport, 2016.
31.
Zhong W, Maradit-Kremers H, St Sauver JL, Yawn BP, Ebbert JO, Roger VL, Jacobson DJ, McGree ME, Brue SM, Rocca WA: Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc 2013; 88: 697–707.
32.
Calcaterra S, Glanz J, Binswanger IA: National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend 2013; 131: 263–270.
33.
van Amsterdam J, van den Brink W: The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev 2015; 8: 3–14.
34.
Weisberg D, Stannard C: Lost in translation? Learning from the opioid epidemic in the USA. Anaesthesia 2013; 68: 1215–1219.
35.
Goldberger N, Haklai Z: Mortality rates in Israel from causes amenable to health care, regional and international comparison. Isr J Health Policy Res 2012; 1: 41.
36.
Sullivan MD, Edlund MJ, Zhang L, Unützer J, Wells KB: Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006; 166: 2087–2093.
37.
Turk DC, Swanson KS, Gatchel RJ: Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008; 24: 497–508.
38.
Lev-Ran S, Feingold D, Frenkel A, Lerner AG: Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. J Dual Diagn 2014; 10: 79–83.
39.
Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC: Prescription opioid abuse in the UK. Br J Clin Pharmacol 2013; 76: 823–824.
40.
European Monitoring Centre for Drugs and Drug Addiction: European Drug Report 2016: Trends and Developments. Luxembourg, 2016.
41.
Tzeitlin T, Shvartzman P: Knowledge, attitudes and skills of family physicians in Israel with regard to chronic pain management in cancer (article in Hebrew). Harefuah 2000; 139: 252–255.
42.
Bachhuber MA, Saloner B, Cunningham CO, Barry CL: Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Int Med 2014; 174: 1668–1673.
43.
Feingold D, Goor-Aryeh I, Bril S, Delayahu Y, Lev-Ran S: Problematic use of prescription opioids and medicinal cannabis among patients suffering from chronic pain. Pain Med 2017; 18: 294–306.
44.
Mechoulam R: Cannabis – the Israeli perspective. J Basic Clin Physiol Pharmacol 2016; 27: 181–187.
45.
Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315–1321.
46.
Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W: An analysis of the root causes for -opioid-related overdose deaths in the United States. Pain Med 2011; 12(suppl 2):S26–S35.
47.
Goldberger BA, Maxwell JC, Campbell A, Wilford BB: Uniform standards and case definitions for classifying opioid-related deaths: recommendations by a SAMHSA consensus panel. J Addict Dis 2013; 32: 231–243.
48.
Goldberger N, Aburbeh M, Haklai Z: Leading Causes of Death in Israel 2000–2014. Jerusalem, Ministry of Health Israel, 2012.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.